Lyme Disease Diagnostics Market, By Diagnostics Test (Enzyme Linked Immunosorbent Assay, Western Blot, and Others), By End User (Hospitals, Clinics, and Diagnostic Laboratories), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Lyme Disease Diagnostics Market is estimated to be valued at USD 1.39 Bn in 2026 and is expected to reach USD 2.20 Bn by 2033, growing at a CAGR of 6.8% from 2026 to 2033. The market is projected to witness steady growth owing to the rising incidence of Lyme disease, increasing demand for early and accurate diagnosis, advancements in molecular and serological diagnostic technologies, and growing government initiatives to strengthen surveillance and control of tick-borne diseases. Lyme disease is a bacterial infection caused primarily by Borrelia burgdorferi and transmitted to humans through the bite of infected blacklegged ticks. Early symptoms include fever, fatigue, headache, muscle and joint pain, and a characteristic skin rash known as erythema migrans. If left untreated, the infection can spread to the joints, nervous system, and heart, resulting in serious health complications. Early and accurate diagnosis is essential for timely treatment and prevention of long-term disease progression. Diagnostic testing typically involves a two-tier testing approach consisting of an initial enzyme-linked immunosorbent assay (ELISA) or enzyme immunoassay (EIA), followed by confirmatory testing using Western blot or modified two-tier testing methods. The market growth is further supported by continuous advancements in diagnostic technologies. Increasing adoption of highly sensitive serological assays, polymerase chain reaction (PCR)-based molecular diagnostics, multiplex testing platforms, and rapid point-of-care diagnostic solutions is improving the accuracy and speed of Lyme disease detection. Growing investments in research and development are enabling manufacturers to introduce innovative diagnostic solutions capable of detecting infection during the early stages, thereby supporting better clinical outcomes. Growing awareness among healthcare professionals and the public regarding the importance of early Lyme disease diagnosis is also contributing to market expansion. Government agencies, public health organizations, and research institutions are actively implementing surveillance programs, awareness campaigns, and laboratory capacity-building initiatives to improve disease detection and reporting. In addition, increasing integration of digital health technologies and artificial intelligence-assisted diagnostic solutions is expected to further enhance diagnostic efficiency and support long-term growth of the Lyme Disease Diagnostics Market during the forecast period. Market Dynamics The Lyme Disease Diagnostics Market is driven by the increasing incidence of Lyme disease, growing demand for early diagnosis, continuous advancements in diagnostic technologies, and expanding government initiatives for surveillance of tick-borne diseases. One of the primary growth drivers is the rising global incidence of Lyme disease. Climate change, expanding tick habitats, changing environmental conditions, and increasing outdoor recreational activities have contributed to the growing prevalence of Lyme disease across several regions. Rising disease awareness, improved healthcare access, and increasing diagnostic testing rates are creating sustained demand for accurate laboratory-based diagnostic solutions. Growing emphasis on early diagnosis to prevent disease progression and reduce long-term complications is expected to support market growth throughout the forecast period. Another major factor driving market expansion is the continuous advancement of molecular and serological diagnostic technologies. Diagnostic manufacturers are developing highly sensitive enzyme-linked immunosorbent assays (ELISA), improved Western blot assays, polymerase chain reaction (PCR)-based molecular diagnostics, multiplex testing platforms, and rapid diagnostic tests capable of delivering faster and more reliable results. These technological innovations are improving diagnostic accuracy while supporting earlier detection of Lyme disease. Increasing adoption of laboratory-based diagnostic testing is also accelerating market growth. Diagnostic laboratories continue to play a critical role in Lyme disease diagnosis by providing centralized testing infrastructure, advanced laboratory equipment, and standardized testing protocols. Growing demand for confirmatory testing, coupled with improvements in laboratory automation and quality assurance systems, is strengthening the adoption of advanced diagnostic solutions across hospitals, clinics, and public health laboratories. Growing government support and surveillance programs are further contributing to market expansion. Public health authorities across several countries are strengthening surveillance systems, expanding laboratory testing capabilities, and promoting awareness regarding early diagnosis and treatment of Lyme disease. Increasing investments in infectious disease monitoring and vector-borne disease control programs are expected to improve access to diagnostic testing and encourage wider adoption of advanced diagnostic technologies. Increasing research and development activities are also supporting market growth. Diagnostic companies, biotechnology firms, and research institutions are actively developing next-generation serological assays, molecular diagnostic platforms, multiplex diagnostics, and artificial intelligence-assisted diagnostic tools aimed at improving clinical accuracy and reducing diagnostic turnaround time. Strategic collaborations, product launches, and continuous technological innovation are expected to expand the diagnostic pipeline and strengthen the competitive landscape. However, the market continues to face challenges including limited diagnostic sensitivity during the early stages of infection, variability in antibody response among patients, lack of standardized testing methods across certain regions, and limited access to advanced diagnostic technologies in developing countries. In addition, high costs associated with advanced molecular testing, reimbursement challenges, and limited awareness in non-endemic regions may restrain market growth. Despite these challenges, continuous technological advancements, expanding government support, increasing public awareness, and growing investments in diagnostic innovation are expected to create significant opportunities for the Lyme Disease Diagnostics Market during the forecast period. Key Features of the Study • This report provides in-depth analysis of the Lyme Disease Diagnostics Market and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year. • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market. • This study also provides key insights about market drivers, restraints, opportunities, new product developments, market trends, regional outlook, and competitive strategies adopted by key players. • It profiles key players in the Lyme Disease Diagnostics Market based on company highlights, product portfolio, key developments, financial performance, and business strategies. • Key companies covered as part of this study include Abbott Laboratories, Bio-Rad Laboratories, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., DiaSorin S.p.A., Revvity, Inc., T2 Biosystems, Inc., IGeneX Inc., Immunetics Inc., ZEUS Scientific, Inc., and Trinity Biotech plc. • Insights from this report would allow marketers, diagnostic manufacturers, healthcare providers, hospitals, clinical laboratories, investors, and management authorities to make informed decisions regarding future product development, market expansion, and strategic collaborations. • The Lyme Disease Diagnostics Market report caters to various stakeholders including diagnostic manufacturers, biotechnology companies, hospitals, diagnostic laboratories, healthcare providers, research organizations, regulatory authorities, investors, distributors, and financial analysts. • Stakeholders would benefit from structured analytical frameworks and strategy matrices used in evaluating the Lyme Disease Diagnostics Market. Market Segmentation • By Diagnostics Test Insights (Revenue, USD Bn, 2021 - 2033) o Enzyme Linked Immunosorbent Assay o Western Blot o Others • By End User Insights (Revenue, USD Bn, 2021 - 2033) o Hospitals o Clinics o Diagnostic Laboratories • By Region Insights (Revenue, USD Mn, 2021 - 2033) o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC Countries  Israel  Rest of Middle East o Africa  South Africa  North Africa  Central Africa • Key Players in the Lyme Disease Diagnostics Market o Abbott Laboratories o Affymetrix Inc. o Alere Inc. o Baxter International Inc. o Bio-Rad Laboratories o Boulder Diagnostics o Canon Life Sciences o Covance Inc. o Fresenius Medical Care AG & Co. o GlaxoSmithKline Pharmaceuticals Ltd. o Roche Diagnostics International Ltd. o Siemens AG o T2 Biosystems o Immunetics Inc.